Shares of Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP - Get Free Report) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.49 and traded as low as $0.43. Elite Pharmaceuticals shares last traded at $0.45, with a volume of 1,712,368 shares trading hands.
Elite Pharmaceuticals Trading Up 2.4%
The firm has a fifty day moving average of $0.43 and a 200 day moving average of $0.49. The firm has a market capitalization of $482.47 million, a PE ratio of -22.58 and a beta of 0.04. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.90 and a current ratio of 3.27.
Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. Elite Pharmaceuticals had a negative net margin of 25.70% and a negative return on equity of 6.92%.
Elite Pharmaceuticals Company Profile
(
Get Free Report)
Elite Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Elite Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elite Pharmaceuticals wasn't on the list.
While Elite Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
